Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Columbia Laboratories has signed an exclusive, five year license and supply agreement with Ascend Therapeutics for the company's Prochieve 4% progesterone gel, currently indicated and FDA-approved for the treatment of secondary amenorrhea.
Subscribe to our email newsletter
Under terms of the agreement, effective January 1, 2008, Ascend Therapeutics will be responsible for marketing and sales of Prochieve 4% in the US using its existing 100-person sales force that calls on a broad range of obstetricians and gynecologists (OB/GYNs). Ascend will purchase product from Columbia at a transfer price equal to 35% of its net selling price with minimum annual purchase obligations that increase over the life of the agreement.
Robert Mills, president and CEO of Columbia Laboratories, said: “We are pleased to announce this exclusive agreement with Ascend Therapeutics, a biopharmaceutical company with an established and growing franchise in women's health. Ascend Therapeutics represents the perfect partner to increase sales of Prochieve 4%, given their ability to effectively reach over 14,000 physicians who are likely to prescribe progesterone but are not on our infertility target list of reproductive endocrinologists and OB/GYNs who treat infertility.”